BCG group and 12 in the control group. One died from REFERENCE another cause in each group. After a follow-up of more than 10 years, the difference in survival is no longer significant for all patients (P=O.I) (Fig 2a). Nevertheless the difference is significant if we consider only stages I and I1 (P=O.O13) (Fig 2b) or high grade malignancy (Kiel’s and W.F. classification) Hcerni. B., Durand. M.. Richaud. P, De Mascarel. A., Hcerni-Simon. G.. Chauvergne, J. & Lagarde. C. (1979) Successful maintenance immunotherapy by BCG of non-Hodgkin’s malignant lymphomas: results of a controlled trial. British journal ojHaematoIogy, 42, 5075 1 4 . (P<0 .05) as was the case 10 years ago. Further follow-up has strengthened our initial findings, supporting the use of adjuvant immunotherapy with BCG in some subsets of non-Hodgkin’s malignant lymphomas. This conclusion is supported by the benefit of BCG therapy for disease-free survival of all patients of our trial: and for actuarial survival and disease-free survival for stages I and I1 or high grade malignancy.
[1]
G. Kandel,et al.
AUTOGRAFT USING PERIPHERAL BLOOD STEM CELLS COLLECTED AFTER HIGH DOSE MELPHALAN IN HIGH RISK MULTIPLE MYELOMA
,
1988,
British journal of haematology.
[2]
I. Lorand-Metze,et al.
Histological and cytological heterogeneity of bone marrow in Philadelphia‐positive chronic myelogenous leukaemia at diagnosis
,
1987,
British journal of haematology.
[3]
R. Bartl,et al.
Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.
,
1986,
Journal of Clinical Pathology.
[4]
R. Bettini,et al.
Bone-marrow patterns and survival in chronic myeloid leukemia.
,
1985,
Haematologica.